Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lipocine (LPCN), Amylyx Pharmaceuticals Inc (AMLX) and Danaher (DHR) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lipocine (LPCN)
Alliance Global Partners analyst Scott Henry maintained a Buy rating on Lipocine today and set a price target of $6.00. The company’s shares closed last Monday at $2.33.
According to TipRanks.com, Henry is ranked 0 out of 5 stars with an average return of
Lipocine has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See today’s best-performing stocks on TipRanks >>
Amylyx Pharmaceuticals Inc (AMLX)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $21.00. The company’s shares closed last Monday at $14.82.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Amylyx Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $24.57, implying a 65.6% upside from current levels. In a report issued on May 5, TD Cowen also maintained a Buy rating on the stock.
Danaher (DHR)
In a report released today, Casey Woodring from J.P. Morgan reiterated a Buy rating on Danaher, with a price target of $245.00. The company’s shares closed last Monday at $169.64.
According to TipRanks.com, Woodring is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $233.74 average price target, which is a 33.6% upside from current levels. In a report issued on April 30, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $206.00 price target.
Read More on LPCN:
